Warning letter follows ban for Chinese API maker Jinan Jinda Pharmaceutical

The FDA has issued a warning letter to Jinan Jinda Pharmaceutical Chemistry, a Chinese API maker whose products have been banned since 2015.

After being put on an import alert by the FDA and running into problems with European regulators, Chinese API maker Jinan Jinda Pharmaceutical Chemistry announced it had hired a consultant to get its plant in order. But in a recent warning letter, the FDA said its efforts are still not enough.

The letter, issued last month, was based on an inspection in June at the plant in Zhangqiu City, Shandong Province, which found lots of problems with scant inspection on out-of-spec test results and plenty of examples of deleted test results.

The letter says that plant’s quality control laboratory disregarded multiple out-of-spec impurity results without justification and then manually reset testing equipment to exclude a peak result. Despite hiring a consultant, the FDA said that the company did not have an adequate interim plan while working to resolve its testing issues.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The FDA found other data integrity concerns, including multiple instances in which data was deleted and said that the company didn’t have adequate safeguards on its computers to prevent the problem.   

The warning letter follows a recommendation in June from the European Directorate for the Quality of Medicines that Jinan Jinda's nitrofurantoin antibiotic be banned from the EU and that the plant's certificate of compliance be suspended or even “voided.” That came after Italian inspectors reported a follow-up visit in which they found raw supplies and finished products in a room in which the door had been screwed shut by employees. Inspectors "concluded there was a serious risk of data falsification" related to the ingredients in the room.

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.